Astellas withdraws lawsuit challenging Medicare drug price negotiation plans
(Reuters) – Japan-based Astellas Pharma on Wednesday withdrew a lawsuit filed against the U.S. government, days after its prostate cancer drug was spared from the first list of drugs that will be subject to Medicare price negotiations. The U.S. government, late last month, selected the first 10 drugs, including the top-selling blood thinner Eliquis from …
Astellas withdraws lawsuit challenging Medicare drug price negotiation plans Read More »









